One of the investments that contributed to our 2012 performance and remains a potential 16 bagger is GCVRZ, a Contingent Value Right (CVR) issued to Genzyme shareholders upon a sale to Sanofi-Aventis (SNY) in 2011.
Broadly speaking, a CVR is a contract that offers contingent future payments to holders of the contract upon the completion of specific predetermined milestones. A CVR can be used in acquisitions, like SNY-GENZ, where the two management teams cannot come to an agreement over the future value of a particular product, in this case a drug to treat multiple sclerosis called Lemtrada.
GCVRZ's value can be divided into two parts: i) a $1 payment for drug approval of Lemtrada by the FDA, which...
Only subscribers can access this article, which is part of the PRO research library covering 3,591 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: